Therapeutic Genome Editing in Cardiovascular Diseases

Research output: Contribution to journalReview article

Abstract

A variety of genetic cardiovascular diseases may one day be curable using gene editing technology. Germline genome editing and correction promises to permanently remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families. Although technically feasible and likely to be ready for implementation in humans in the near future, this approach remains ethically controversial. Although currently beset by several technical challenges, and not yet past small animal models, somatic genome editing may also be useful for a variety of cardiovascular disorders. It potentially avoids ethical concerns about permanent editing of the germline and allows treatment of already diseased individuals. If technical challenges of Cas9-gRNA delivery (viral vector immune response, nonviral vector delivery) can be worked out, then CRISPR-Cas9 may have a significant place in the treatment of a wide variety of disorders in which partial or complete gene knockout is desired. However, CRISPR may not work for gene correction in the human heart because of low rates of homology directed repair. Off-target effects also remain a concern, although, thus far, small animal studies have been reassuring. Some of the therapies mentioned in this review may be ready for small clinical trials in the near future.

Original languageEnglish (US)
Pages (from-to)122-131
Number of pages10
JournalJACC: Basic to Translational Science
Volume4
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Cardiovascular Diseases
Guide RNA
Gene Knockout Techniques
Inborn Genetic Diseases
Therapeutics
Animal Models
Clinical Trials
Technology
Genes
Gene Editing

Keywords

  • CRISPR
  • gene editing
  • germline gene correction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Therapeutic Genome Editing in Cardiovascular Diseases. / German, David M.; Mitalipov, Shoukhrat; Mishra, Anusha; Kaul, Sanjiv.

In: JACC: Basic to Translational Science, Vol. 4, No. 1, 01.02.2019, p. 122-131.

Research output: Contribution to journalReview article

@article{f4775d826328497eb42f98d5d78ff0ff,
title = "Therapeutic Genome Editing in Cardiovascular Diseases",
abstract = "A variety of genetic cardiovascular diseases may one day be curable using gene editing technology. Germline genome editing and correction promises to permanently remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families. Although technically feasible and likely to be ready for implementation in humans in the near future, this approach remains ethically controversial. Although currently beset by several technical challenges, and not yet past small animal models, somatic genome editing may also be useful for a variety of cardiovascular disorders. It potentially avoids ethical concerns about permanent editing of the germline and allows treatment of already diseased individuals. If technical challenges of Cas9-gRNA delivery (viral vector immune response, nonviral vector delivery) can be worked out, then CRISPR-Cas9 may have a significant place in the treatment of a wide variety of disorders in which partial or complete gene knockout is desired. However, CRISPR may not work for gene correction in the human heart because of low rates of homology directed repair. Off-target effects also remain a concern, although, thus far, small animal studies have been reassuring. Some of the therapies mentioned in this review may be ready for small clinical trials in the near future.",
keywords = "CRISPR, gene editing, germline gene correction",
author = "German, {David M.} and Shoukhrat Mitalipov and Anusha Mishra and Sanjiv Kaul",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jacbts.2018.11.004",
language = "English (US)",
volume = "4",
pages = "122--131",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Therapeutic Genome Editing in Cardiovascular Diseases

AU - German, David M.

AU - Mitalipov, Shoukhrat

AU - Mishra, Anusha

AU - Kaul, Sanjiv

PY - 2019/2/1

Y1 - 2019/2/1

N2 - A variety of genetic cardiovascular diseases may one day be curable using gene editing technology. Germline genome editing and correction promises to permanently remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families. Although technically feasible and likely to be ready for implementation in humans in the near future, this approach remains ethically controversial. Although currently beset by several technical challenges, and not yet past small animal models, somatic genome editing may also be useful for a variety of cardiovascular disorders. It potentially avoids ethical concerns about permanent editing of the germline and allows treatment of already diseased individuals. If technical challenges of Cas9-gRNA delivery (viral vector immune response, nonviral vector delivery) can be worked out, then CRISPR-Cas9 may have a significant place in the treatment of a wide variety of disorders in which partial or complete gene knockout is desired. However, CRISPR may not work for gene correction in the human heart because of low rates of homology directed repair. Off-target effects also remain a concern, although, thus far, small animal studies have been reassuring. Some of the therapies mentioned in this review may be ready for small clinical trials in the near future.

AB - A variety of genetic cardiovascular diseases may one day be curable using gene editing technology. Germline genome editing and correction promises to permanently remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families. Although technically feasible and likely to be ready for implementation in humans in the near future, this approach remains ethically controversial. Although currently beset by several technical challenges, and not yet past small animal models, somatic genome editing may also be useful for a variety of cardiovascular disorders. It potentially avoids ethical concerns about permanent editing of the germline and allows treatment of already diseased individuals. If technical challenges of Cas9-gRNA delivery (viral vector immune response, nonviral vector delivery) can be worked out, then CRISPR-Cas9 may have a significant place in the treatment of a wide variety of disorders in which partial or complete gene knockout is desired. However, CRISPR may not work for gene correction in the human heart because of low rates of homology directed repair. Off-target effects also remain a concern, although, thus far, small animal studies have been reassuring. Some of the therapies mentioned in this review may be ready for small clinical trials in the near future.

KW - CRISPR

KW - gene editing

KW - germline gene correction

UR - http://www.scopus.com/inward/record.url?scp=85061393042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061393042&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2018.11.004

DO - 10.1016/j.jacbts.2018.11.004

M3 - Review article

AN - SCOPUS:85061393042

VL - 4

SP - 122

EP - 131

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

SN - 2452-302X

IS - 1

ER -